Andelyn Biosciences Partners with Amplo Biotechnology to Manufacture AAV Gene Therapies for Neuromuscular Junction Disorders

Andelyn Biosciences has announced a collaboration with Amplo Biotechnology to support the manufacturing of adeno-associated virus (AAV) gene therapies. The partnership focuses on advancing treatments for neuromuscular junction (NMJ) disorders, leveraging Andelyn’s expertise in viral vector production and Amplo’s innovative therapeutic approaches.

The agreement will involve Andelyn providing manufacturing capabilities to produce AAV-based gene therapies developed by Amplo. These therapies aim to address conditions affecting NMJ function, which play a critical role in communication between nerves and muscles. Both companies have expressed their commitment to accelerating the development process and ensuring high-quality production standards for these potential treatments. Further details regarding the timeline or specific NMJ conditions targeted have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 22, 2025

Author

Mark Chiang